Apr 16, 2019
FDA gives thumbs-up to Balversa The U.S. FDA has granted approval of Balversa (erdafitinib) to Belgium-based Janssen Pharmaceutica, for the treatment of advanced or metastatic bladder cancer. This drug is the first ever approved target-specific medication targeting susceptible FGFR genetic mutations, and for can...
Read More...
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper